This morning Allergy Therapeutics has announced the enrolment of the first ten US patients in its GrassMATAMPL (GMM) 204 phase II study (G204). This is part of the clinical programme for the company's development of Pollinex Quattro Grass for the US which, with today's news, we see tracking on plan. Not only does this show progress against the timetable it also serves as a reminder of the breadth of the business which, with the recent £11.5m (gross) fund-raise has seen the company acqui
